Skip to main content
Premium Trial:

Request an Annual Quote

Iconix Inks Biomarker Research Deal with Brigham and Women s Hospital Researcher

NEW YORK, Sept. 20 (GenomeWeb News) - Iconix Pharmaceuticals said today that it has signed an agreement to work with Roderick Jensen, acting director of the biotechnology center and laboratory for functional genomics at the Brigham and Women's Hospital, on the study and validation of gene expression patterns in patients with neurological diseases.

 

According to Iconix, Jensen's lab has developed a high-throughput validation strategy that uses multiple gene expression platforms to assay tissue samples. The partnership aims to validate gene expression changes in human peripheral blood for diagnostics, prognostics, and drug response. Jensen's strategy, Iconix said, will be tested in patients with Parkinson's disease.

 

In March, at the 43rd Annual Society of Toxicology Meeting in Baltimore, Md., Iconix said that it would publicly release a subset of its proprietary genomic biomarker data to researchers who agree to make their findings public.

 

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.